333.80

0.71% 2.36

After Hours: 333.39 -0.41 -0.12%

Medpace Holdings Inc (MEDP)

Overview News Price History Option Chain Financials Discussions Forecast

Medpace Holdings Inc stock is traded at $333.80, with a volume of 339.48K. It is up +0.71% in the last 24 hours and down -6.04% over the past month. Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Previous Close:

$331.44

Open:

$330.07

24h Volume:

339.48K

Relative Volume:

1.09

Market Cap:

$10.27B

Revenue:

$2.03B

Net Income/Loss:

$339.79M

P/E Ratio:

39.09

EPS:

8.54

Net Cash Flow:

$502.80M

1W Performance:

-7.78%

1M Performance:

-6.04%

6M Performance:

-17.41%

1Y Performance:

+37.86%

1-Day Range:

$328.39

$334.43

1-Week Range:

$319.70

$363.83

52-Week Range:

$227.21

$459.77

Medpace Holdings Inc Stock (MEDP) Company Profile

Name

Medpace Holdings Inc

Sector

Healthcare (1190)

Industry

Diagnostics & Research (58)

Phone

(513) 579-9911

Address

5375 MEDPACE WAY, CINCINNATI, OH

Employee

5,800

Twitter

@WorkatMedpace

Next Earnings Date

2024-10-21

Latest SEC Filings

MEDP's Discussions on Twitter

Medpace Holdings Inc Stock (MEDP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Upgrade	UBS	Neutral → Buy
Oct-24-23	Upgrade	Robert W. Baird	Neutral → Outperform
May-08-23	Upgrade	Guggenheim	Neutral → Buy
Oct-27-22	Upgrade	UBS	Sell → Neutral
Sep-07-22	Initiated	UBS	Sell
May-24-22	Initiated	Guggenheim	Neutral
Aug-05-21	Resumed	Credit Suisse	Outperform
Oct-02-20	Upgrade	Truist	Hold → Buy
Jun-08-20	Upgrade	Robert W. Baird	Underperform → Neutral
May-13-20	Downgrade	Wolfe Research	Outperform → Peer Perform
Apr-30-20	Upgrade	SunTrust	Sell → Hold
Apr-20-20	Downgrade	Robert W. Baird	Neutral → Underperform
Mar-17-20	Downgrade	SunTrust	Hold → Sell
Jan-27-20	Downgrade	SunTrust	Buy → Hold
Oct-31-18	Upgrade	SunTrust	Hold → Buy
Sep-17-18	Initiated	SunTrust	Hold
Jul-31-18	Upgrade	William Blair	Mkt Perform → Outperform
Nov-01-17	Downgrade	William Blair	Outperform → Mkt Perform
Sep-29-17	Initiated	Raymond James	Mkt Perform
Jul-10-17	Downgrade	KeyBanc Capital Mkts	Overweight → Sector Weight

View All

Medpace Holdings Inc Stock (MEDP) Latest News

06:55 AM

Driehaus Capital Management LLC Purchases 26,726 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) - MarketBeat

06:55 AM

Sep 29, 2024

MEDP INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Medpace Holdings, Inc. and Encourages Investors to Contact the Firm - PR Newswire

Sep 29, 2024

Thrivent Financial for Lutherans Increases Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP) - MarketBeat

Sep 29, 2024

Sep 28, 2024

Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Vulcan Value Partners LLC - MarketBeat

Sep 28, 2024

Sep 27, 2024

UBS Downgrades Medpace Holdings (MEDP) - MSN

Sep 27, 2024

MEDP INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire

Sep 27, 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Stockholders to Learn More About the Investigation - AccessWire

Sep 27, 2024

UBS downgrades Medpace stock citing biotech funding and bookings challenges - Investing.com India

Sep 27, 2024

62,432 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Purchased by Point72 Asset Management L.P. - MarketBeat

Sep 27, 2024

UBS downgrades Medpace stock citing biotech funding and bookings challenges - Investing.com

Sep 27, 2024

UBS downgrades Medpace stock citing biotech funding and bookings challenges - Investing.com UK

Sep 27, 2024

StockNews.com Downgrades Medpace (NASDAQ:MEDP) to Hold - MarketBeat

Sep 27, 2024

Sep 26, 2024

Medpace (MEDP) Outperforms Broader Market: What You Need to Know - Yahoo Finance

Sep 26, 2024

Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Investors to Inquire about Securities Investigation - AccessWire

Sep 26, 2024

Medpace, Fortrea cut as Jefferies reviews CROs amid biotech headwinds - MSN

Sep 26, 2024

D. E. Shaw & Co. Inc. Sells 72,214 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) - MarketBeat

Sep 26, 2024

Jefferies Downgrades Medpace Holdings (MEDP) - MSN

Sep 26, 2024

Sep 25, 2024

U.S. Indexes Finished Mixed Wednesday As Duolingo Led, Medpace Holdings Lagged - Barron's

Sep 25, 2024

Medpace stock 'faces downside risk' amid biotech funding struggles, says Jefferies - Investing.com India

Sep 25, 2024

Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Cubist Systematic Strategies LLC - MarketBeat

Sep 25, 2024

Medpace stock 'faces downside risk' amid biotech funding struggles, says Jefferies - Investing.com

Sep 25, 2024

Sep 24, 2024

MEDP (Medpace Holdings) GF Score : 94/100 (As of Sep. 24, 2024) - GuruFocus.com

Sep 24, 2024